Haemonetics
270 hedge funds and large institutions have $3.83B invested in Haemonetics in 2022 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 84 increasing their positions, 101 reducing their positions, and 21 closing their positions.
152% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 21
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more capital invested
Capital invested by funds: $3.39B → $3.83B (+$439M)
12% more funds holding
Funds holding: 241 → 270 (+29)
0.5% less ownership
Funds ownership: 101.35% → 100.85% (-0.5%)
9% less call options, than puts
Call options by funds: $4.6M | Put options by funds: $5.08M
17% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 101
Top Buyers
| 1 |
Millennium Management
New York
|
+$29M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.3M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$15.7M |
| 4 |
Neuberger Berman Group
New York
|
+$12.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.4M |
Top Sellers
HAE Hedge Fund Activity: Q3 2022 in Review
270 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2022, worth a combined $3.83B — up 13% from $3.39B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new HAE positions and 21 closed out — a net gain of 32 holders — while 84 added to existing stakes and 101 trimmed.
The largest buyer was Millennium Management, adding an estimated $29M. The largest seller was Citadel Advisors, cutting an estimated $45.3M.
- 270 institutional investors held Haemonetics (HAE) as of Q3 2022, up from 241 in Q2 2022.
- Funds reported $3.83B of Haemonetics stock for Q3 2022, up 13% quarter-over-quarter.
- 53 funds opened new Haemonetics positions in Q3 2022 and 21 closed out, a net change of +32 holders.
- The largest Haemonetics buyer in Q3 2022 was Millennium Management, an estimated $29M added.
- The largest Haemonetics seller in Q3 2022 was Citadel Advisors, an estimated $45.3M sold.
Based on aggregated 13F filings for Q3 2022.